Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment

被引：0
|
作者：
William L. Marshall
Hwa-Ping Feng
Larissa Wenning
Graigory Garrett
Xiaobi Huang
Fang Liu
Deborah Panebianco
Luzelena Caro
Christine Fandozzi
Kenneth C. Lasseter
Richard A. Preston
Thomas Marbury
Joan R. Butterton
Marian Iwamoto
Wendy W. Yeh
机构：
[1] Merck & Co.,Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine
[2] Inc.,undefined
[3] Clinical Pharmacology of Miami,undefined
[4] Florida International University,undefined
[5] Orlando Clinical Research Center,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2018年 / 43卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：321 / 329
页数：8
相关论文
共 50 条
  • [1] Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment
    Marshall, William L.
    Feng, Hwa-Ping
    Wenning, Larissa
    Garrett, Graigory
    Huang, Xiaobi
    Liu, Fang
    Panebianco, Deborah
    Caro, Luzelena
    Fandozzi, Christine
    Lasseter, Kenneth C.
    Preston, Richard A.
    Marbury, Thomas
    Butterton, Joan R.
    Iwamoto, Marian
    Yeh, Wendy W.
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (03) : 321 - 329
  • [2] Pharmacokinetics and Safety of Single-dose Atogepant in Participants with Hepatic Impairment
    Boinpally, R.
    Jakate, A.
    Butler, M.
    Borbridge, L.
    Periclou, A.
    [J]. HEADACHE, 2020, 60 : 45 - 46
  • [3] Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
    Vidya Perera
    Grigor Abelian
    Danshi Li
    Zhaoqing Wang
    Liping Zhang
    Susan Lubin
    Wei Chen
    Akintunde Bello
    Bindu Murthy
    [J]. Clinical Pharmacokinetics, 2022, 61 : 857 - 867
  • [4] Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
    Perera, Vidya
    Abelian, Grigor
    Li, Danshi
    Wang, Zhaoqing
    Zhang, Liping
    Lubin, Susan
    Chen, Wei
    Bello, Akintunde
    Murthy, Bindu
    [J]. CLINICAL PHARMACOKINETICS, 2022, 61 (06) : 857 - 867
  • [5] Hepatic impairment does not alter the single-dose pharmacokinetics and safety of entecavir
    Bifano, M
    Yan, JH
    Xie, J
    Zhang, D
    Freund, J
    Grasela, D
    LaCreta, F
    [J]. ANTIVIRAL THERAPY, 2004, 9 (06) : H23 - H24
  • [6] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Fontes, Magda S. C.
    Dingemanse, Jasper
    Halabi, Atef
    Tomaszewska-Kiecana, Monika
    Sidharta, Patricia N.
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [7] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Magda S. C. Fontes
    Jasper Dingemanse
    Atef Halabi
    Monika Tomaszewska-Kiecana
    Patricia N. Sidharta
    [J]. Scientific Reports, 12
  • [8] Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants
    Fan, Bin
    Dai, David
    Cohen, Marvin
    Xu, Huansheng
    Yin, Feng
    Nagaraja, Raj
    Mobilia, Michelle
    Almon, Caroline
    Basile, Frank G.
    Yang, Hua
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (01): : 99 - 109
  • [9] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
  • [10] Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment
    Lawitz, Eric
    Parmar, Deven
    Momin, Taufik
    Shaikh, Farheen
    Patel, Harilal
    Hayes, Helen
    Swint, Kimberly
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (12): : 1142 - 1155
12345